<!--
  ~ Copyright (c) 2017. Dana-Farber Cancer Institute. All rights reserved.
  ~
  ~  Licensed under the GNU Affero General Public License, Version 3.0 (the "License");
  ~  you may not use this file except in compliance with the License.
  ~
  ~ See the file LICENSE in the root of this repository.
  ~
  ~ Contributing authors:
  ~ - berndvdveen
  ~
  -->
<div class="card-body card-padding">
    <h3 class="md-title">Contact</h3>
    <p>
      For detailed methodology and protocol, please contact the Center for Advanced Molecular Diagnostics (857-307-1500).
    </p>
    <h3 class="md-title">
      References
    </h3>
    <p>
     <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353152/">Wagle et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012</a>
    </p>
    <p>
      These tests were developed and their performance characteristics determined by the Molecular Diagnostics Laboratory, Brigham and Womenâ€™s Hospital. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
    </p>
</div>
